64857 The impact of continuous secukinumab treatment through week 104 on efficacy outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trialsAlexa B. Kimball, Jacek C. Szepietowski, D. Ioannides et al.|Journal of the American Academy of Dermatology|2025Cited by 0
64674 The impact of continuous secukinumab treatment through week 104 on patient reported outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trialsAlexa B. Kimball, Jacek C. Szepietowski, Steven Daveluy et al.|Journal of the American Academy of Dermatology|2025Cited by 0